July 21, 2011 -- CTMG, Inc. announced the recent completion of Isis Pharmaceutical’s Phase III hyperlipidemia study, entitled, “A Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of ISIS 301012 (Mipomersen) As Add-on Therapy in High Risk Hypercholesterolemic Patients” in which three CTMG physician investigator offices were top enrolling sites in the United States. The study officially opened in November of 2008. Three CTMG Business Associate Physician Investigator sites were brought up in August and September of 2009: Natalie Doyle, MD, in Wilson, NC (top enrolling center); Richard Shultzaberger, MD, of Physicians East in Greenville, NC (second highest enrolling center), and Mark Cervi, MD of Eastern Internal Medicine also in Greenville, NC). While the study opened with approximately 60 other physician centers in late 2008, CTMG sites reached the required enrollment in only three months. The three CTMG physician investigative centers enrolled 30 of the 158 study patients nationwide, or nearly 19% of total enrollment. The remaining 81% of the patients were enrolled across the other 60 physician centers.
CTMG has offices in Greenville, NC, Durham, NC and Raleigh, NC. For Business Development inquiries, please contact:
David Holland (Business Development Manager)